Medline ® Abstract for Reference 16
of 'Drug-induced immune thrombocytopenia'
16
TI
Hematologic effects of linezolid: summary of clinical experience.
AU
Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ
SO
Antimicrob Agents Chemother. 2002;46(8):2723.
Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at>or =2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.
AD
Division of Hematology/Oncology and Ireland Cancer Center, Case Western Reserve University, University Hospitals of Cleveland, 10900 Euclid Avenue, Cleveland, OH 44106-4937, USA. slg5@cwru.edu
PMID